<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="publisher-id">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20711287</article-id><article-id pub-id-type="pmc">2918305</article-id><article-id pub-id-type="publisher-id">IJPsy-47-84</article-id><article-id pub-id-type="doi">10.4103/0019-5545.55951</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Paper</subject></subj-group></article-categories><title-group><article-title>Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Avasthi</surname><given-names>Ajit</given-names></name><xref ref-type="aff" rid="AF0001">*</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Kulhara</surname><given-names>Parmanand</given-names></name><xref ref-type="aff" rid="AF0002">**</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Gagandeep</given-names></name><xref ref-type="aff" rid="AF0005">***</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Rajni</given-names></name><xref ref-type="aff" rid="AF0004">****</xref></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>Rajinder P.</given-names></name><xref ref-type="aff" rid="AF0003">*****</xref></contrib></contrib-group><aff id="AF0001"><label>*</label>Additional Professor of Psychiatry, Postgraduate Institute of Medical Education and Research</aff><aff id="AF0002"><label>**</label>Professor and Head of Psychiatry, Postgraduate Institute of Medical Education and Research</aff><aff id="AF0003"><label>*****</label>Clinical Psychologist, Department of Psychiatry Postgraduate Institute of Medical Education and Research</aff><aff id="AF0004"><label>****</label>Play Therapist, Department of Paediatrics Postgraduate Institute of Medical Education and Research</aff><aff id="AF0005"><label>***</label>Senior Lecturer of Psychiatry, Government Medical College and Hospital, Chandigarh</aff><author-notes><corresp id="cor1"><italic>Correspondence to:</italic><bold>Ajit Avasthi,</bold> Additional Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research Chandigarh 160012; e-mail: <email xlink:href="medinst@pgi.chd.nic.in">medinst@pgi.chd.nic.in</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2005</year></pub-date><volume>47</volume><issue>2</issue><fpage>84</fpage><lpage>88</lpage><permissions><copyright-statement>&#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2005</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.</p></sec><sec id="st2"><title>Aim:</title><p>To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder.</p></sec><sec id="st3"><title>Methods:</title><p>In this prospective study, patients (<italic>n</italic>=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery&#x02013;Asberg Depression Scale (MADRS).</p></sec><sec id="st4"><title>Results:</title><p>Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile.</p></sec><sec id="st5"><title>Conclusion:</title><p>Moclobemide is an effective antidepressant and is better tolerated than imipramine.</p></sec></abstract><kwd-group><kwd>Moclobemide</kwd><kwd>depression</kwd><kwd>monoamine oxidase-A inhibitor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Depression is a major public health problem, causing subjective distress, impaired functional capacity, secondary mental and somatic complications and increase in mortality. An accurate diagnosis followed by efficient treatment can improve the outcome.<xref ref-type="bibr" rid="CIT1">1</xref></p><p>Classically, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have been used to treat depression. For the past two decades, researchers have aspired to develop clinically effective antidepressants with a more rapid onset of action and/or less troublesome side-effects. These efforts led to the development of selective serotonin reuptake inhibitors (SSRIs), selective norepi-nephrine reuptake inhibitors (SNRIs) and reversible inhibitors of monoamine oxidase (RIMA).<xref ref-type="bibr" rid="CIT2">2</xref></p><p>Although MAOIs were among the first substances to be used as antidepressants, due to their &#x02018;cheese effects&#x02019;, they largely fell into disuse in the 1960s.<xref ref-type="bibr" rid="CIT3">3</xref> Moclobemide, a benzamide, is one of the new generation MAOIs which belongs to the class of RIMA. It selectively inhibits monoamine oxidase-A (MAO-A) and does not affect other enzyme systems.<xref ref-type="bibr" rid="CIT2">2</xref> The inhibition of monoamine oxidase-A, which is reversible, imparts two important clinical characteristics to this drug. First, minimal potentiation occurs in case of high availability of tyramine (as a substrate in food), hence, the risk of hypertensive crisis after intake of tyramine-rich food is negligible.<xref ref-type="bibr" rid="CIT4">4</xref> Second, after termination of moclobemide treatment, MAO activity returns to normal within one day.<xref ref-type="bibr" rid="CIT5">5</xref> Both animal and human pharmacological studies have established that no clinically significant interaction occurs if moclobemide is taken after consumption of tyramine in physiological amounts.<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT6">6</xref><xref ref-type="bibr" rid="CIT7">7</xref> In addition, its non-affinity for muscarinic, dopaminergic, serotoninergic, opioid or benzodiazepine receptors protects against the development of a host of adverse reactions seen in case of TCAs.<xref ref-type="bibr" rid="CIT2">2</xref></p><p>Previous studies comparing moclobemide and placebo in patients with major depressive disorder found moclobemide to be significantly better than the placebo.<xref ref-type="bibr" rid="CIT8">8</xref>&#x02013;<xref ref-type="bibr" rid="CIT10">10</xref> Moclobemide is found to be well-tolerated and equally effective as other antidepressants, i.e. heterocyclic compounds such as imipramine,<xref ref-type="bibr" rid="CIT11">11</xref><xref ref-type="bibr" rid="CIT12">12</xref> amitriptyline,<xref ref-type="bibr" rid="CIT13">13</xref><xref ref-type="bibr" rid="CIT14">14</xref> clomipramine,<xref ref-type="bibr" rid="CIT15">15</xref><xref ref-type="bibr" rid="CIT16">16</xref> SSRIs such as fluoxetine,<xref ref-type="bibr" rid="CIT17">17</xref><xref ref-type="bibr" rid="CIT18">18</xref> sertraline<xref ref-type="bibr" rid="CIT19">19</xref> and older MAO inhibitors such as tranylcypramine.<xref ref-type="bibr" rid="CIT20">20</xref> These findings were reconfirmed in a meta-analysis of RIMA-type A moclobemide and brofarmine in the treatment of major depression.<xref ref-type="bibr" rid="CIT21">21</xref> Gagiano <italic>et al</italic>.<xref ref-type="bibr" rid="CIT22">22</xref> established the usefulness and safety of moclobemide for continuation treatment of major depressive episodes. The most commonly reported adverse effects of moclobemide are insomnia (13%), nausea (11%), headache (11%), dizziness (6%), agitation (3%) and diarrhoea (3%).<xref ref-type="bibr" rid="CIT23">23</xref></p><p>Despite overwhelming data from western countries, there is no evidence available from India regarding its efficacy and tolerability. We evaluated the efficacy and safety of moclobemide in comparison with the TCA imipramine in the treatment of depression in Indian patients.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>Patients attending the outpatient clinic of a tertiary-care teaching hospital were selected for the study. Men and women between the ages of 18 and 50 years, fulfilling the ICD-10 criteria for major depression,<xref ref-type="bibr" rid="CIT24">24</xref> and having a minimum score of 18 on the 24-item Hamilton Depression Rating Scale (HDRS)<xref ref-type="bibr" rid="CIT25">25</xref> and 25 on the Montgomery&#x02013;Asberg Depression Rating Scale (MADRS)<xref ref-type="bibr" rid="CIT26">26</xref> were included in the study. Patients who had been administered a clinically effective dose of antidepressants in the preceding 2 weeks, electroconvulsive therapy (ECT) in the preceding 3 months, those on MAO inhibitors, and those with concurrent physical or co-morbid psychiatric illness (including substance abuse) were excluded from the study. All patients gave their informed consent to participate in the study. The approval of Ethics Committee and permission from the Drug Controller General of India (DCGI) were obtained before initiating the study.</p><p>It was an open, randomized, comparative study of 6 weeks' duration. Of the 60 patients enrolled in the trial, 30 were randomized to receive moclobemide and 30 imipramine. The sociodemographic data of both the groups revealed that the majority of patients were men (55%), married (80%), educated up to matriculation (71%), employed (55%) and hailed from nuclear families (55%) of urban background (55%). The two groups did not differ significantly in any of these sociodemo-graphic variables.</p><p>The patients underwent a detailed physical examination, and clinical as well as laboratory investigations. Moclobemide was started at a dose of 300 mg daily (2 &#x000d7; 150 mg) or 75 mg imipramine daily as per the study protocol. The dosage was increased at an interval of not less than 1 week to a maximum of 600 mg for moclobemide daily or 300 mg for imipramine daily if there was no clinical improvement/clinical deterioration, or less than 20% improvement in the scores of the HDRS during the study period.</p><sec id="sec2-1"><title>Study population</title><p>Twenty patients (33.3%) did not complete the 6-week treatment period; 9 (30%) on moclobemide, 11 (36.7%) on imipramine. In moclobemide group, of the 9 patients, 3 were lost to follow-up, while 2 each had poor compliance, refused treatment and developed a new set of symptoms. In the imipramine group, 2 patients discontinued treatment due to adverse effects, 3 were lost to follow-up and 3 each refused treatment and developed a new set of symptoms.</p><p>Of the 30 patients in each group, 24 in each group fulfilled the criteria for &#x02018;Intent to treat&#x02019; patients. &#x02018;Intent to treat&#x02019; was defined as patients either completing the study protocol or had received the minimal possible intended dose and did not include those patients who had poor compliance/refused treatment or developed a new set of symptoms.</p><p>The safety and tolerability of treatment were evaluated at the end of weeks 1, 2, 4, and 6 based on vital signs (heart rate, blood pressure), laboratory values (baseline and post-treatment) and adverse effects.</p><p>The efficacy was evaluated at the end of week 2, 4, and 6 based on scores on the HDRS and MADRS. A responder was defined as one showing a decrease of at least 50% in the scores on the MADRS or the HDRS from the baseline.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-2"><title>Efficacy</title><sec id="sec3-1"><title>1. Hamilton Depression Rating Scale (HDRS)</title><p>In the &#x02018;treatment completers&#x02019;, there was a steady decrease in depression rating in both the treatment groups, with the mean total score falling from 29.14 (SD&#x000b1;5.64) at baseline to 12.95 (SD&#x000b1;8.17) at the end of 6 weeks in the moclobemide group, and from 29.68 (SD&#x000b1;4.43) to 8.52 (SD&#x000b1;7.16) in the imipramine group. The change in both the groups from the baseline to the end of week 6 was statistically significant (p&#x0003c;0.001). The mean changes and percentage reductions of the HDRS scores in week 0&#x02013;2, week 2&#x02013;4, week 4&#x02013;6 and week 0&#x02013;6 were significant (p&#x0003c;0.001) but comparable across both the groups (<xref ref-type="table" rid="T0001">Table 1</xref>).</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Mean changes and percentage reduction in the scores on the Hamilton Depression Rating Scale (HDRS) in &#x02018;treatment completers&#x02019;</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Moclobemide (<italic>n</italic>=21)</th><th align="center" colspan="2" rowspan="1">Imipramine (<italic>n</italic>=19)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1"><hr/></th><th align="left" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Duration (in weeks)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 2</td><td align="center" rowspan="1" colspan="1">7.48</td><td align="center" rowspan="1" colspan="1">25.66<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">11.47</td><td align="center" rowspan="1" colspan="1">38.64<xref ref-type="table-fn" rid="T000F1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 2&#x02013;week 4</td><td align="center" rowspan="1" colspan="1">5.62</td><td align="center" rowspan="1" colspan="1">25.94<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">5.16</td><td align="center" rowspan="1" colspan="1">28.33<xref ref-type="table-fn" rid="T000F1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 4&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">3.09</td><td align="center" rowspan="1" colspan="1">19.26<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">4.53</td><td align="center" rowspan="1" colspan="1">34.71<xref ref-type="table-fn" rid="T000F1">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">16.19</td><td align="center" rowspan="1" colspan="1">55.56<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">21.16</td><td align="center" rowspan="1" colspan="1">71.29<xref ref-type="table-fn" rid="T000F1">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T000F1"><label>*</label><p>p&#x0003c;0.001</p></fn></table-wrap-foot></table-wrap><p>In the &#x02018;Intent to treat&#x02019; patients, the mean scores on the HDRS fell from 29.50 (SD&#x000b1;5.05) at baseline to 14.04 (SD&#x000b1;8.96) at the end of 6 weeks in the moclobemide group and from 30.25 (SD&#x000b1;4.28) at baseline to 11.71 (SD&#x000b1;8.43) at the end of 6 weeks in the impramine group. The change in both the groups from baseline to the end of week 6 was statistically significant (p&#x0003c;0.001). The mean changes and percentage reductions in the HDRS scores in week 0&#x02013;2, week 2&#x02013;4, week 4&#x02013;6 and week 0&#x02013;6 were significant (p&#x0003c;0.001) but comparable across both the groups (<xref ref-type="table" rid="T0002">Table 2</xref>).</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Mean changes and percentage reduction in the scores on the Hamilton Depression Rating Scale (HDRS) in the &#x02018;Intent to treat patients&#x02019; group</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Moclobemide (<italic>n</italic>=24)</th><th align="center" colspan="2" rowspan="1">Imipramine (<italic>n</italic>=24)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1"><hr/></th><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Duration (in weeks)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 2</td><td align="center" rowspan="1" colspan="1">7.42</td><td align="center" rowspan="1" colspan="1">25.14<xref ref-type="table-fn" rid="T000F2">*</xref></td><td align="center" rowspan="1" colspan="1">11.67</td><td align="center" rowspan="1" colspan="1">38.57<xref ref-type="table-fn" rid="T000F2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 2&#x02013;week 4</td><td align="center" rowspan="1" colspan="1">5.08</td><td align="center" rowspan="1" colspan="1">23.00<xref ref-type="table-fn" rid="T000F2">*</xref></td><td align="center" rowspan="1" colspan="1">4.04</td><td align="center" rowspan="1" colspan="1">21.74<xref ref-type="table-fn" rid="T000F2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 4&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">2.96</td><td align="center" rowspan="1" colspan="1">17.41<xref ref-type="table-fn" rid="T000F2">*</xref></td><td align="center" rowspan="1" colspan="1">2.83</td><td align="center" rowspan="1" colspan="1">19.46<xref ref-type="table-fn" rid="T000F2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">15.46</td><td align="center" rowspan="1" colspan="1">52.41<xref ref-type="table-fn" rid="T000F2">*</xref></td><td align="center" rowspan="1" colspan="1">18.54</td><td align="center" rowspan="1" colspan="1">61.29<xref ref-type="table-fn" rid="T000F2">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T000F2"><label>*</label><p>p&#x0003c;0.001</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-2"><title>2. Montgomery&#x02013;Asberg Scale (MADRS)</title><p>In &#x02018;treatment completers&#x02019; the mean total score fell from 36.47 (SD&#x000b1;6.58) at baseline to 18.42 (SD&#x000b1;11.47) at week 6 in the moclobemide group, and from 36.26 (SD&#x000b1;5.50) to 12.15 (SD&#x000b1;8.57) in the imipramine group. Although the changes between baseline and week 2, week 2 and 4, and baseline and week 6 were statistically significant, they were comparable across both the groups. The change in score from week 4&#x02013;6 in the moclobemide group was statistically less significant than that in the imipramine group (p&#x0003c;0.05 vs p&#x0003c;0.001) (<xref ref-type="table" rid="T0003">Table 3</xref>).</p><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Mean changes and percentage reduction in the scores on the Montgomery&#x02013;Asberg Depression Scale (MADRS) in &#x02018;treatment completers&#x02019;</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Moclobemide (<italic>n</italic>=21)</th><th align="center" colspan="2" rowspan="1">Imipramine (<italic>n</italic>=19)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1"><hr/></th><th align="left" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Duration (in weeks)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 2</td><td align="center" rowspan="1" colspan="1">7.57</td><td align="center" rowspan="1" colspan="1">20.75<xref ref-type="table-fn" rid="T000F3">*</xref></td><td align="center" rowspan="1" colspan="1">10.42</td><td align="center" rowspan="1" colspan="1">28.73<xref ref-type="table-fn" rid="T000F3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 2&#x02013;week 4</td><td align="center" rowspan="1" colspan="1">6.43</td><td align="center" rowspan="1" colspan="1">22.24<xref ref-type="table-fn" rid="T000F3">*</xref></td><td align="center" rowspan="1" colspan="1">7.21</td><td align="center" rowspan="1" colspan="1">27.90<xref ref-type="table-fn" rid="T000F3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 4&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">4.05</td><td align="center" rowspan="1" colspan="1">18.02<xref ref-type="table-fn" rid="T000F4">**</xref></td><td align="center" rowspan="1" colspan="1">6.47</td><td align="center" rowspan="1" colspan="1">34.78<xref ref-type="table-fn" rid="T000F3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">18.05</td><td align="center" rowspan="1" colspan="1">49.49<xref ref-type="table-fn" rid="T000F3">*</xref></td><td align="center" rowspan="1" colspan="1">24.11</td><td align="center" rowspan="1" colspan="1">66.49<xref ref-type="table-fn" rid="T000F3">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T000F3"><label>*</label><p>p&#x0003c;0.001;</p></fn><fn id="T000F4"><label>**</label><p>p&#x0003c;0.05</p></fn></table-wrap-foot></table-wrap><p>As shown in <xref ref-type="table" rid="T0004">Table 4</xref>, the mean total score on MADRS in the &#x02018;intent to treat&#x02019; group fell from 36.83 (SD&#x000b1;6.31) at baseline to 19.96 (SD&#x000b1;12.23) at week 6 in the moclobemide group, and from 37.00 (SD&#x000b1;5.66) to 16.08 (SD&#x000b1;10.61) in the imipramine group. Although the changes between baseline and week 2, week 2 and 4 and baseline and week 6 were statistically significant, they were comparable across the two groups. The change of score in week 4&#x02013;6 in the moclobemide group was statistically less significant than that in the imipramine group (p&#x0003c;0.05 vs p&#x0003c;0.001).</p><table-wrap id="T0004" position="float"><label>Table 4</label><caption><p>Mean changes and percentage reduction in the scores on the Montgomery&#x02013;Asberg Depression Scale (MADRS) in the &#x02018;Intent to treat patients&#x02019; group</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Moclobemide (<italic>n</italic>=24)</th><th align="center" colspan="2" rowspan="1">Imipramine (<italic>n</italic>=24)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1"><hr/></th><th align="left" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Duration (in weeks)</th><th align="center" rowspan="1" colspan="1">Mean changes</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th><th align="center" rowspan="1" colspan="1">Meanchanges</th><th align="center" rowspan="1" colspan="1">Reduction (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 2</td><td align="center" rowspan="1" colspan="1">7.00</td><td align="center" rowspan="1" colspan="1">19.00<xref ref-type="table-fn" rid="T000F5">*</xref></td><td align="center" rowspan="1" colspan="1">11.92</td><td align="center" rowspan="1" colspan="1">32.21<xref ref-type="table-fn" rid="T000F5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 2&#x02013;week 4</td><td align="center" rowspan="1" colspan="1">6.04</td><td align="center" rowspan="1" colspan="1">20.25<xref ref-type="table-fn" rid="T000F5">*</xref></td><td align="center" rowspan="1" colspan="1">5.16</td><td align="center" rowspan="1" colspan="1">20.57<xref ref-type="table-fn" rid="T000F5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Week 4&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">3.83</td><td align="center" rowspan="1" colspan="1">16.10<xref ref-type="table-fn" rid="T000F6">**</xref></td><td align="center" rowspan="1" colspan="1">3.84</td><td align="center" rowspan="1" colspan="1">19.28<xref ref-type="table-fn" rid="T000F5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline&#x02013;week 6</td><td align="center" rowspan="1" colspan="1">16.87</td><td align="center" rowspan="1" colspan="1">45.81<xref ref-type="table-fn" rid="T000F5">*</xref></td><td align="center" rowspan="1" colspan="1">20.92</td><td align="center" rowspan="1" colspan="1">56.53<xref ref-type="table-fn" rid="T000F5">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T000F5"><label>*</label><p>p&#x0003c;0.001;</p></fn><fn id="T000F6"><label>**</label><p>p&#x0003c;0.05</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec2-3"><title>Responders</title><p>Sixty-two per cent of patients belonging to the moclobemide group and 84% in the imipramine group were responders on the HDRS. There were 52.38% responders in the moclobe-mide group and 73.68% in the imipramine group on MADRS. Overall, the patients on imipramine responded better than those on moclobemide at the end of 6 weeks.</p></sec><sec id="sec2-4"><title>Safety and tolerability</title><p>Moclobemide appears to be better tolerated than imipramine. Anticholinergic side-effects were reported less often by patients on moclobemide as compared with imipramine&#x02014;dry mouth in 6 patients (20%) vs 9 (30%), constipation in 1 (3.33%) vs 11 (36%), blurred vision in 3 (10%) vs 6 (20%) (<xref ref-type="table" rid="T0005">Table 5</xref>).</p><table-wrap id="T0005" position="float"><label>Table 5</label><caption><p>Treatment-emergent side-effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Side-effect</th><th align="center" rowspan="1" colspan="1">Moclobemide (<italic>n</italic>=30)</th><th align="center" rowspan="1" colspan="1">Imipramine (<italic>n</italic>=30)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dry mouth</td><td align="center" rowspan="1" colspan="1">6 (20.00)</td><td align="center" rowspan="1" colspan="1">9 (33.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blurred vision</td><td align="center" rowspan="1" colspan="1">3 (10.00)</td><td align="center" rowspan="1" colspan="1">6 (20.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td><td align="center" rowspan="1" colspan="1">3 (10.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="center" rowspan="1" colspan="1">2 (6.66)</td><td align="center" rowspan="1" colspan="1">6 (20.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sweating</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">4 (13.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">2 (6.66)</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td><td align="center" rowspan="1" colspan="1">11 (36.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Postural hypotension</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (6.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild sedation</td><td align="center" rowspan="1" colspan="1">1 (3.33)</td><td align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difficulty in swallowing</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (6.66)</td></tr></tbody></table><table-wrap-foot><fn><p>Values in parentheses are percentages.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>This study compares the efficacy and safety of moclobemide with that of imipramine in the treatment of major depressive disorder in Indian patients. The drugs were found to have comparable efficacy as measured by the HDRS and MADRS. Studies comparing the efficacy of moclobemide with that of other TCAs such as imipramine<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref><xref ref-type="bibr" rid="CIT11">11</xref> and amitriptyline<xref ref-type="bibr" rid="CIT27">27</xref> have reported similar results. The rapidity of improvement as measured by the decrease in scores on the HDRS and MADRS in successive weeks were similar in both the groups. These results are in accordance with that of previous studies.<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref><xref ref-type="bibr" rid="CIT11">11</xref> The change in scores in week 4&#x02013;6 was found to be statistically less significant in the moclobemide than the imipramine group (p=0.05 vs p=0.001). No previous study has found such a change. It could be because common side-effects encountered with imipramine therapy decrease considerably by the end of this period. This may be responsible for the greater decrease in the scores. Studies with double-blind measures and a larger sample size can solve this riddle. Rimon <italic>et al</italic>.<xref ref-type="bibr" rid="CIT2">2</xref> reported faster onset of antidepressant action in the moclobemide than the imipramine group as measured by assessment of investigators on a scale of &#x02018;Very Good&#x02019; to &#x02018;No Change&#x02019;. However, the onset of action was similar in both the groups as measured by a decrease in the HDRS scores. The present study also found a similar onset of action in both the groups as measured by a reduction in the HDRS and MADRS scale scores. It strengthens the observation that measurements of onset of action should be done in terms of scale measurements rather than simple clinical impressions.</p><p>Although the change in scores from the baseline to week 6 was comparable on both the HDRS and MADRS in both the groups, there were a significantly larger number of responders in the imipramine group. This could be due to the greater reduction in the HDRS and MADRS scores in weeks 4&#x02013;6. These results might suggest somewhat better response for imipramine in achieving clinical response. However, these findings should be interpreted in the light of the fact that definition of clinical response in this study was an arbitrary one and this was an open, non-blind, randomized trial.</p><p>As observed in other studies,<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref><xref ref-type="bibr" rid="CIT11">11</xref> anticholinergic side-effects such as dry mouth, constipation, blurring of vision were more common in patients treated with imipramine than with moclobemide. The most common side-effects encountered with moclobemide were dry mouth (20%) and blurred vision (10%). However, no patient discontinued treatment due to these adverse effects. On the other hand, 6 patients in the imipramine group discontinued treatment due to the adverse effects. Hence, the overall tolerability of moclobemide is much better than that of imipramine as shown in earlier studies.<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref> Highly selective affinity towards MAO-A and almost no affinity for muscarinic, dopa-minergic, serotoninergic, opioid or benzodiazepine receptors might be responsible for its greater tolerability and fewer side-effects.</p><p>To conclude, moclobemide is a safe and effective antidepressant with a favourable side-effect profile.</p></sec></body><back><ack><p>We acknowledge the support of the Protec division of Cipla Limited, India for this clinical trial.</p></ack><ref-list><title>REFERENCES</title><ref id="CIT1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Akiskal</surname><given-names>HS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sadock</surname><given-names>BJ</given-names></name><name><surname>Sadock</surname><given-names>VA</given-names></name></person-group><article-title>Mood disorders: Introduction and overview</article-title><source>Comprehensive textbook of psychiatry</source><year>2000</year><volume>Vol I</volume><edition>7th ed</edition><publisher-loc>Baltimore</publisher-loc><publisher-name>Williams &#x00026; Wilkins</publisher-name><fpage>1284</fpage><lpage>7</lpage></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimon</surname><given-names>R</given-names></name><name><surname>Jaaskelainen</surname><given-names>J</given-names></name><name><surname>Kaartinen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Moclobemide versus imipramine in depressed out-patients: A double-blind multi-centre study</article-title><source>Int Clin Psychopharmacol</source><year>1993</year><volume>7</volume><fpage>141</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8468435</pub-id></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versiani</surname><given-names>M</given-names></name><name><surname>Oggero</surname><given-names>U</given-names></name><name><surname>Alterwain</surname><given-names>P</given-names></name><etal/></person-group><article-title>A double blind comparative trial of moclobemide vs. imipramine and placebo in major depression episodes</article-title><source>Br J Psychiatry</source><year>1989</year><volume>155</volume><fpage>72</fpage><lpage>7</lpage><comment>(Suppl 6)</comment></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkard</surname><given-names>WP</given-names></name><name><surname>Bonetti</surname><given-names>EP</given-names></name><name><surname>Da Prada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacological profile of moclobemide&#x02013;a short acting and reversible inhibitor of monoamine oxidase type A</article-title><source>J Pharmacol Exp Ther</source><year>1989</year><volume>248</volume><fpage>391</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2913284</pub-id></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barclay</surname><given-names>CA</given-names></name></person-group><article-title>Clinical pharmacology of moclobemide&#x02014;pharmacodynamic and pharmacokinetic aspects</article-title><source>Moclobemide, a new MAO inhibitor for the treatment of depression</source><year>1988</year><publisher-name>Hexagon Roche</publisher-name><fpage>11</fpage><lpage>15</lpage></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gieschke</surname><given-names>R</given-names></name><name><surname>Schmid-Burgk</surname><given-names>W</given-names></name><name><surname>Amrein</surname><given-names>R</given-names></name></person-group><article-title>Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine</article-title><source>Journal of Neural Transmission</source><year>1988</year><volume>26</volume><fpage>97</fpage><lpage>104</lpage><comment>(Suppl.)</comment><pub-id pub-id-type="pmid">3283292</pub-id></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid-Burgk</surname><given-names>W</given-names></name><name><surname>Gieschke</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name></person-group><article-title>Moclobemide, a new reversible MAO inhibitor and the problem of tyramine interaction studies</article-title><source>Curr Ther Res</source><year>1988</year><volume>43</volume><fpage>903</fpage><lpage>17</lpage></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casacchia</surname><given-names>M</given-names></name><name><surname>Caroei</surname><given-names>A</given-names></name><name><surname>Barba</surname><given-names>C</given-names></name></person-group><article-title>A placebo-controlled study of the antidepressant activity of moclobemide. A new MAO-A inhibitor</article-title><source>Pharmacopsychiatry</source><year>1984</year><volume>17</volume><fpage>122</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6382361</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botte</surname><given-names>L</given-names></name><name><surname>Gilles</surname><given-names>C</given-names></name><name><surname>Evarard</surname><given-names>JL</given-names></name></person-group><article-title>Moclobemide versus placebo in the treatment of depression: A multicentre study in Belgium</article-title><source>Acta Psychiatr Scand</source><year>1990</year><volume>82</volume><fpage>42</fpage><lpage>4</lpage><comment>(Suppl 360)</comment></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ose</surname><given-names>E</given-names></name><name><surname>Holm</surname><given-names>P</given-names></name></person-group><article-title>Moclobemide and placebo in mild/major depression: A double blind randomized trial</article-title><source>Psychopharma-cology</source><year>1992</year><volume>106</volume><fpage>114</fpage><lpage>15</lpage><comment>(Suppl.)</comment></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumhackl</surname><given-names>U</given-names></name><name><surname>Biziere</surname><given-names>K</given-names></name><name><surname>Fischbach</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder. (DSM-III): An Austrian double-blind multicentre study</article-title><source>Br J Psychiatry</source><year>1989</year><volume>155</volume><fpage>78</fpage><lpage>83</lpage><comment>(Suppl 6)</comment></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstone</surname><given-names>T</given-names></name></person-group><article-title>Moclobemide versus imipramine in bipolar depression: A multicentre double-blind clinical trial</article-title><source>Acta Psychiatr Scand</source><year>2001</year><volume>104</volume><fpage>104</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11473503</pub-id></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>TR</given-names></name><name><surname>Ames</surname><given-names>D</given-names></name><name><surname>Burrows</surname><given-names>GD</given-names></name></person-group><article-title>A controlled study of a specific MAO-A reversible inhibitor (R0 11-1163) and amitriptyline in depressive illness</article-title><source>J Affect Disord</source><year>1985</year><volume>8</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">3156909</pub-id></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newburn</surname><given-names>GM</given-names></name><name><surname>Fraser</surname><given-names>AR</given-names></name><name><surname>Menkes</surname><given-names>DB</given-names></name></person-group><article-title>A double-blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders</article-title><source>Aus N Z J Psychiatry</source><year>1990</year><volume>24</volume><fpage>475</fpage><lpage>9</lpage></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>JK</given-names></name><name><surname>Holm</surname><given-names>P</given-names></name><name><surname>Mikkelsen</surname><given-names>PL</given-names></name></person-group><article-title>Moclobemide and clomipramine in the treatment of depression</article-title><source>Acta Psychiatr Scand</source><year>1984</year><volume>70</volume><fpage>254</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">6388247</pub-id></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dierick</surname><given-names>M</given-names></name><name><surname>Cattiez</surname><given-names>P</given-names></name><name><surname>Franck</surname><given-names>G</given-names></name><etal/></person-group><article-title>Moclobemide vs clomipramine in the treatment of depression: A double-blind multicentre study in Belgium</article-title><source>Acta Psychiatr Scand</source><year>1990</year><volume>82</volume><fpage>50</fpage><lpage>1</lpage><comment>(Suppl.360)</comment></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattaz</surname><given-names>WF</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Kick</surname><given-names>H</given-names></name><etal/></person-group><article-title>Moclobemide versus fluoxetine in the treatment of inpatients with major depression</article-title><source>J Clin Psychopharmacol</source><year>1995</year><volume>15</volume><fpage>35S</fpage><lpage>40S</lpage><comment>(Suppl)</comment><pub-id pub-id-type="pmid">7593728</pub-id></element-citation></ref><ref id="CIT18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapierre</surname><given-names>YD</given-names></name><name><surname>Joffe</surname><given-names>R</given-names></name><name><surname>McKenna</surname><given-names>K</given-names></name><etal/></person-group><article-title>Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults</article-title><source>J Psychiatry Neurosci</source><year>1997</year><volume>22</volume><fpage>118</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9074306</pub-id></element-citation></ref><ref id="CIT19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orsel Donbak</surname><given-names>S</given-names></name><name><surname>Turkcapar</surname><given-names>MH</given-names></name><name><surname>Ozturk Kilic</surname><given-names>EZ</given-names></name><etal/></person-group><article-title>Moclobemide and sertraline in the treatment of depressive disorders: A comparative study</article-title><source>Acta Psychiatr Belgium</source><year>1995</year><volume>95</volume><fpage>139</fpage><lpage>51</lpage></element-citation></ref><ref id="CIT20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinze</surname><given-names>G</given-names></name><name><surname>Rossel</surname><given-names>L</given-names></name><name><surname>Gabelic</surname><given-names>I</given-names></name><etal/></person-group><article-title>Double blind trial of moclobemide and tranylcypramine in depression</article-title><source>Pharmaco-psychiatry</source><year>1993</year><volume>26</volume><fpage>240</fpage><lpage>5</lpage></element-citation></ref><ref id="CIT21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotufo-Neto</surname><given-names>F</given-names></name><name><surname>Trivedi</surname><given-names>M</given-names></name><name><surname>Thase</surname><given-names>M</given-names></name></person-group><article-title>Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofarmine in the treatment of major depression</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>20</volume><fpage>226</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">10063483</pub-id></element-citation></ref><ref id="CIT22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagiano</surname><given-names>CA</given-names></name><name><surname>Muller</surname><given-names>FG</given-names></name><name><surname>de Kock</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Moclobemide in continuation treatment of major depressive episodes: An open follow up study over six months</article-title><source>J Clin Psychopharmacol</source><year>1995</year><volume>15</volume><fpage>46S</fpage><lpage>50S</lpage><comment>(Suppl.)</comment><pub-id pub-id-type="pmid">7593731</pub-id></element-citation></ref><ref id="CIT23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiller</surname><given-names>JW</given-names></name><name><surname>Johnson</surname><given-names>GF</given-names></name><name><surname>Burrows</surname><given-names>GD</given-names></name></person-group><article-title>Moclobemide for depression: An Australian practice study</article-title><source>J Clin Psycho-pharmacol</source><year>1995</year><volume>15</volume><fpage>31S</fpage><lpage>34S</lpage><comment>(Suppl)</comment></element-citation></ref><ref id="CIT24"><label>24</label><element-citation publication-type="book"><collab>World Health Organization</collab><source>The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines</source><year>1992</year><publisher-loc>New Delhi</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="CIT25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>A rating scale for depression</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1960</year><volume>23</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14399272</pub-id></element-citation></ref><ref id="CIT26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>S</given-names></name><name><surname>Asberg</surname><given-names>A</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change</article-title><source>Br J Psychiatry</source><year>1979</year><volume>134</volume><fpage>382</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">444788</pub-id></element-citation></ref><ref id="CIT27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakish</surname><given-names>D</given-names></name><name><surname>Bradwejn</surname><given-names>J</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name></person-group><article-title>A comparison of moclobemide, amitriptyline and placebo in depression: A Canadian multicentre study</article-title><source>Psychopharmacology</source><year>1992</year><volume>106</volume><fpage>98</fpage><lpage>101</lpage><comment>(Suppl.)</comment></element-citation></ref></ref-list></back></article>